Teva reports Q3 2026 results, raises full‑year outlook and announces FDA approval for WELTRUZA
Teva Pharmaceutical Industries posted third‑quarter 2026 revenue of $4.4 billion, down 2% year‑over‑year, and non‑GAAP diluted EPS of $0.86, beating analyst forecasts. The company raised its 2026 revenue guidance to $16.7‑$17.0 billion and its non‑GAAP EPS guidance to $1.92‑$2.11, citing strong growth of its innovative brands Austedo, Ajovy and Uzedy, which each grew about 33% in local‑currency sales. Teva also received FDA approval for the long‑acting injectable schizophrenia treatment WELTRUZA and completed the acquisition of BXCL‑501.
Why it matters
The raised guidance expands Teva’s projected revenue and earnings for 2026, which could improve valuation multiples for investors (the company’s own outlook says revenue now expected $16.7‑$17.0 billion). The FDA approval adds a new product to Teva’s long‑acting injectable franchise, potentially increasing future sales in the schizophrenia market.
Key facts
- 1Q3 2026 revenue was $4.4 billion, a 2% decline year‑over‑year in both U.S. dollars and local currency. stocktitan.net
- 2Non‑GAAP diluted EPS for the quarter was $0.86, a 10% increase year‑over‑year. stocktitan.net
- 3Full‑year 2026 revenue guidance was raised to $16.7‑$17.0 billion. rttnews.com
- 4Full‑year 2026 non‑GAAP diluted EPS guidance was raised to $1.92‑$2.11. rttnews.com
- 5Austedo revenue grew 21% to $751 million; Ajovy grew 61% to $269 million; Uzedy grew 96% to $85 million, together generating about $1.1 billion and driving a 33% local‑currency growth of the innovative brand segment. finanznachrichten.de
- 6Teva received FDA approval for WELTRUZA, a long‑acting injectable schizophrenia treatment. finanznachrichten.de
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.